Iterum Therapeutics plc
iterumtx.com
Security Operations
Professional Services
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Iterum Therapeutics Limited is dedicated to developing significantly differentiated anti-infectives aimed at combatting MDR pathogens.
News
Iterum Therapeutics Reports Third Quarter 2025 Financial Results
--Commercially Launched ORLYNVAH in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasd
Read more
Report
Iterum Therapeutics sees cash runway into 2026
Iterum Therapeutics (ITRM) provided a general business update. ORLYNVAH Launch Update: In partnership with EVERSANA Life Science Services, ORLYNVAH was launched in August 2025 into the community market in the U.S. in targeted territories across seven stat
Read more
Report
Iterum Therapeutics announces FDA approval of Orlynvah
Iterum Therapeutics (ITRM) plc announced that the U.S. Food and Drug Administration has approved Iterum's new drug application for Orlynvah for the treatment of uncomplicated urinary tract infections, or uUTIs, caused by the designated microorganisms Esch
Read more
Report